What do systematic reviews say?

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  RR 0.55 [0.26, 1.19]
  1 study · 40 participants
  Very low

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 224 participants
  GRADE not reported

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  GRADE not reported

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  RR 0.1 [0.01, 1.94]
  1 study · 40 participants
  Very low

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 224 participants
  GRADE not reported

Intervention not reported

The intervention leads to higher smoking cessation at longest (high certainty).

• Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation 2019 · Cochrane Headline outcomes only
  RR 1.15 [1.08, 1.22]
  65 studies · 23331 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate